DIAGNOSIS YEAR
Select the diagnosis year first. J’Onco Mentor uses it to establish the standards cycle and to drive year-sensitive routing in this module.
Explore lung anatomy
Select one or more lung lobes on the realistic anatomy diagram. The application will calculate the suggested ICD-O-3 primary site from all selected sites and the documented pattern of involvement. Patient right appears on the left. Realistic regions are approximate educational overlays. Other visible structures are labeled for reference only and are not selectable.
Realistic anterior thoracic view. Select multiple lung lobes independently. Each selected lobe remains highlighted; click that same lobe again to remove it. Other organ names are read-only labels. Patient right appears on the left.
Other thoracic anatomy — reference labels only
These structures help orient the lung diagram. They are not clickable and do not change ICD-O-3 coding, tumor laterality, or staging. Labels are approximate; some structures (including the esophagus) are partially obscured in an anterior view.
* Posterior structure shown for orientation; its exact position is not visible in this projection. Labels are not intended as a diagnostic anatomical atlas.
Cancer histology and ICD-O-3 coding
Selected lung sites & calculated primary site
Multiple lobes may be selected at the same time. Click a selected lobe again to remove it. The calculated topography is synchronized to the ICD-O-3 Topography / Primary Site field.
No lung anatomy selected.
Main bronchi are C34.0; lobar bronchi map to their lung lobes. A segmental bronchus requires documented site-of-origin verification. For a single lesion overlapping two or more lung lobes with no determinable point of origin, use C34.8. Multiple tumors in different lobes of one lung abstracted as a single primary are coded C34.9. Bilateral selections require review under the Lung Solid Tumor Rules and are not collapsed automatically into one C34 code. Laterality remains a separate registry data item.
Associated biomarkers to learn
Lung Multiple Primary Rules & Calculator
Educational decision support based on the current SEER Solid Tumor Rules 2027 update. Use the official manual for final abstraction decisions.
1. Confirm a lung primary
Before applying the Lung rules, determine that the tumor represents a primary lung malignancy rather than metastasis from another organ/site.
2. Review number and location of tumors
Document whether there is one tumor or multiple separate/non-contiguous tumors, whether tumors are in the same lung or both lungs, and which lobes or bronchial subsites are involved.
3. Compare histology
Determine whether the tumors have the same histology, different histologies, or different subtypes/variants. Different histologic families can support multiple-primary decisions under the applicable rule.
4. Neuroendocrine vs non-small cell
Pay special attention when one tumor is a neuroendocrine tumor/carcinoma and another is a non-small cell carcinoma. This distinction is specifically addressed by the Lung Solid Tumor Rules.
5. Tumors in both lungs
Bilateral lung tumors are not automatically one primary. Apply the Lung multiple-primary rules using tumor number, histology, timing, and documentation before assigning one topography.
6. Assign histology using the rules
Use the Lung histology rules when more than one histologic term or component is documented. The rules determine which histology to code and when a mixed or more specific code applies.
Guided multiple-primary review
Select the tumor pattern, location, and histology relationship to see what should be reviewed in the official Lung Solid Tumor Rules.
Important lung-rule reminders
- Rule sequencing matters. Stop at the first rule that applies.
- The rules determine both the number of primaries to abstract and the histology to code.
- Do not infer one primary solely because tumors are in the same lung or because they share a topography code.
- Do not infer multiple primaries solely because tumors are bilateral.
- For histology, do not code “features” or “differentiation” unless a specific ICD-O code exists for that recognized entity.
AJCC STAGING
PATHOLOGIC STAGING CRITERIA — LUNG
Qualifying evidence: Resection specimens (wedge, segmentectomy, lobectomy or pneumonectomy) generally permit pathological assessment of tumor size and extent (pT). Regional lymph node sampling or dissection supports pN; assess nodal stations and laterality under the applicable lung chapter.
pT / pN: Assign only categories supported by the actual pathological evidence and the site-specific AJCC rules. A diagnosis-confirming biopsy does not automatically establish a pathological primary tumor category.
pM: Pathologically proven distant metastasis may support pM1 where the chapter permits; AJCC does not use pM0.
Treatment sequence: Distinguish initial pathological classification (pTNM) from post-neoadjuvant classification (ypTNM). Confirm eligibility, histology, staging chapter and diagnosis-year edition before finalizing.
Source / verification: AJCC · SEER tools and manuals. Educational overview only; verify exact chapter-specific criteria in the licensed AJCC manual.
Lung AJCC staging schema / TNM context
Use the T, N and M controls and site-specific factors below. Verify final AJCC ID, TNM edition and stage group in the approved AJCC/SEER staging system for the diagnosis year.
AJCC Staging Schema
Schema eligibility is based on diagnosis year, primary site, and histology. This educational summary does not replace the AJCC manual or SEER*RSA.
C34.0 Main bronchus · C34.1 Upper lobe · C34.2 Middle lobe · C34.3 Lower lobe · C34.8 Overlapping lesion · C34.9 Lung, NOS
Version 9: 8000–8700, 8720–8790, 8972, 8980, 8982.
T = primary tumor extent/size · N = regional lymph nodes · M = distant metastasis. The lymph-node tool provides an educational suggested N category only.
What Changed in AJCC Version 9? — Lung
Key lung-specific differences from AJCC 8th Edition for diagnosis years 2025+.
N2a = involvement of a single N2 nodal station. N2b = involvement of multiple N2 nodal stations.
M1c1 = multiple extrathoracic metastases within one organ system. M1c2 = multiple extrathoracic metastases in multiple organ systems.
Selected T/N combinations moved to different stage groups in Version 9. Examples include T1 N1 M0 → Stage IIA, T1 N2a M0 → Stage IIB, and T3 N2a M0 → Stage IIIA.
No major restructuring of the lung T categories was introduced; the major operational changes are in N, M, and stage grouping.
Spread Through Air Spaces (STAS) is recognized as a histopathologic descriptor in the Version 9 lung framework, but it is not itself a T, N, or M category.
TNM Stage Group Calculator
The diagnosis year above determines the AJCC edition used for grouping. Clinical and pathologic stage groups are calculated separately. This is an informational staging aid and does not replace the AJCC manual.
Clinical TNM
Pathologic TNM
AJCC reminder: pM0 is not a valid category. For a pathologic stage group without distant metastasis, the M component remains clinical (cM0); pathologic M categories apply when distant metastasis is microscopically confirmed.
Lung Surgery Codes
Surgical Procedure of Primary Site 2023 codes for lung C34.0–C34.9. Select a code to view its registry description.
Surgical Procedure of Primary Site
Stage and Treatment
Select a stage, then choose from the treatment options shown for that stage. This is an educational NCCN-aligned reference, not a patient-specific recommendation.
Select a stage to populate the Treatment dropdown.
For NSCLC, biomarker testing can materially change systemic treatment selection, especially in advanced disease. For SCLC, limited-stage and extensive-stage pathways differ substantially.
Built as an educational overview using current NCCN lung cancer guidance, with NCI/ACS stage-based treatment summaries used as public cross-checks. Verify the current NCCN version before clinical use.
Site-Specific Data Items (SSDI)
These are educational SSDI topic prompts, not a validated complete schema-specific SSDI list or coded values. Determine applicable items, collection requirements, definitions, codes and effective years from the official SSDI Manual and schema before abstracting.
NAACCR SSDI database ↗ · SEER SSDI resources ↗AJCC / SEER EOD lung staging eligibility
This is a histology-range and primary-site screening aid based on published SEER EOD lung schemas, not a complete AJCC eligibility determination or stage assignment. Verify behavior, coding year, edition, and special histology schemas.
SEER EOD Lung V9 (2025+) · SEER EOD Lung 8th (2018–2024)Localized sites and regional spread — SEER Summary Stage 2018
Confined to lung or qualifying superficial bronchial disease; adjacent ipsilateral lobe can be localized under Summary Stage rules.
Examples include visceral pleural invasion, chest wall, mediastinum, trachea, or a separate tumor nodule in the same lobe. Exact documentation and applicable version govern.
Ipsilateral bronchial, hilar, intrapulmonary, interlobar, lobar, segmental, subsegmental, mediastinal, subcarinal and paratracheal nodes (when qualifying).
Both qualifying regional direct extension and regional lymph node involvement, without distant spread.
Examples include supraclavicular nodes, contralateral or bilateral hilar/mediastinal nodes, and distant organ metastases. Summary Stage is not identical to AJCC TNM.
Extent cannot be determined from available documentation under applicable rules.
Regional nodal classification depends on the side of the primary. The selected lobe and histology alone do not establish stage. This is an educational overview, not an automatic staging determination.
SEER*RSA Lung Summary Stage 2018 definitions · Current Summary Stage Manual and revisions
Interactive IASLC lymph node stations — realistic thoracic anatomy
Click the numbered markers over the realistic thoracic illustration to select positive stations. Patient right is on the left in this anterior view. The background is an AI-generated educational illustration; marker placement is schematic and must not be used to determine exact IASLC station boundaries. Station numbers are anatomical identifiers, not EOD Regional Nodes codes.
Suggested AJCC N category from selected positive stations
Click any lymph node station to mark it positive.
One-click selection: Every station you click is automatically positive. Click again to remove it. No additional status entry is needed.
Visual reference only: the background illustration is not a validated IASLC map. Use the official IASLC definitions to resolve station boundaries and staging questions.
No stations selected.
Note: Station 3 is designated 3A (prevascular) and 3P (retrotracheal), not 3R/3L. Station 1 nodes are AJCC N3 but distant under SEER Summary Stage for lung. Mediastinal stations 2–9 require attention to laterality and anatomical boundaries. A station designation alone does not establish pathologic nodal involvement or stage.
IASLC · SEER EOD Regional Nodes (Lung) · SEER Summary Stage Manual
Regional lymph nodes identified by code — Lung EOD Regional Nodes
NAACCR item #774 · SEER EOD Regional Nodes, Lung schema. These are three-digit EOD codes, not AJCC N categories, ICD-O codes, or one-digit Summary Stage codes. The descriptions below are for educational lookup; check the applicable schema version for the diagnosis year.
| EOD code | Anatomical nodes / status | SS2018 mapping |
|---|---|---|
| 000 | No regional lymph node involvement | None |
| 300 | Ipsilateral hilar / bronchial: hilar (bronchopulmonary), peribronchial, intrapulmonary, interlobar, lobar, segmental and subsegmental nodes; typically stations 10–14 | Regional nodes |
| 400 | Ipsilateral mediastinal: carinal/tracheobronchial, subcarinal (station 7), paratracheal, pretracheal, paraesophageal, pulmonary ligament, and other qualifying mediastinal nodes; includes mediastinal NOS as defined in schema | Regional nodes |
| 600 | Ipsilateral or contralateral: low cervical, scalene, supraclavicular, sternal-notch nodes | Distant |
| 700 | Contralateral or bilateral: qualifying hilar, bronchial or mediastinal nodes (review schema-specific details) | Distant |
| 800 | Regional lymph node(s), NOS / lymph node(s), NOS | Regional nodes |
| 999 | Unknown / cannot assess / not documented | Unknown |
EOD Regional Nodes codes such as 400, 600, and 700 are three-digit EOD values and should not be read as Summary Stage codes 4, 6, or 7.
For lung, some nodal findings that AJCC categorizes as N3 may map to Summary Stage 7 (distant). The AJCC N category and SEER Summary Stage answer different staging questions and should be interpreted separately.
SEER Summary Stage 2018 — Complete Code Reference
SEER*RSA: Lung EOD Regional Nodes codes · SEER Training: Lung nodal stations · Separate pleural Summary Stage reference
AJCC staging
Lung chapter / staging framework: exact AJCC version and schema must be checked against diagnosis year and applicable eligibility rules. This MVP does not automatically assign stage.
COMMON METASTATIC SITES — LUNG
Lung cancer can spread to many organs. The following are among the main distant metastatic sites identified by NCI.
Brain
Frequent distant site; document confirmed brain involvement in Mets at Dx and staging fields.
Bone
Common hematogenous site of spread.
Liver
Common distant organ involvement.
Adrenal gland
Classic distant metastatic site for lung primaries.
Other lung
Contralateral pulmonary involvement may represent distant disease depending on the documented pattern and staging rules.
Sources
All external source links used throughout J'Onco Mentor are collected here for convenient review.
Reference-checked seed content, not a substitute for current diagnosis-year-specific manuals. Biomarkers and treatment categories are illustrative and require separate clinical review before production use.